(VIANEWS) – Live Nation Entertainment (LYV), Amphastar Pharmaceuticals (AMPH), Dycom Industries (DY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Live Nation Entertainment (LYV)
45.3% sales growth and 55.49% return on equity
Live Nation Entertainment, Inc. operates as a live entertainment company. It operates through Concerts, Ticketing, and Sponsorship & Advertising segments. The Concerts segment promotes live music events in its owned or operated venues, and in rented third-party venues; operates and manages music venues; produces music festivals; creates and streams associated content; and offers management and other services to artists. The Ticketing segment manages the ticketing operations, including the provision of ticketing software and services to clients for tickets and event information through its primary websites livenation.com and ticketmaster.com, as well as through other websites, mobile apps, retail outlets, and call centers; and provides ticket resale services. This segment sells tickets for its events and third-party clients in various live event categories; offers ticketing services for arenas, stadiums, amphitheaters, music clubs, concert promoters, professional sports franchises and leagues, college sports teams, performing arts venues, museums, and theaters. The Sponsorship & Advertising segment sells international, national, and local sponsorships and placement of advertising, including signage and promotional programs; rich media offering that comprise advertising related with live streaming and music-related content; and ads across its distribution network of venues, events, and websites. This segment also manages the development of strategic sponsorship programs, as well as develops, books, and produces custom events or programs for specific brands. It owns, operates, or leases entertainment venues in North America and internationally. The company was formerly known as Live Nation, Inc. and changed its name to Live Nation Entertainment, Inc. in January 2010. Live Nation Entertainment, Inc. was incorporated in 2005 and is headquartered in Beverly Hills, California.
Earnings Per Share
As for profitability, Live Nation Entertainment has a trailing twelve months EPS of $1.5.
PE Ratio
Live Nation Entertainment has a trailing twelve months price to earnings ratio of 62.89. Meaning, the purchaser of the share is investing $62.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 55.49%.
Yearly Top and Bottom Value
Live Nation Entertainment’s stock is valued at $94.33 at 00:22 EST, under its 52-week high of $101.74 and way above its 52-week low of $64.25.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.5%, now sitting on 21.2B for the twelve trailing months.
2. Amphastar Pharmaceuticals (AMPH)
34% sales growth and 24.59% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $2.56.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 22.74. Meaning, the purchaser of the share is investing $22.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.59%.
Yearly Top and Bottom Value
Amphastar Pharmaceuticals’s stock is valued at $58.22 at 00:22 EST, way below its 52-week high of $67.66 and way above its 52-week low of $27.58.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Amphastar Pharmaceuticals’s EBITDA is 5.26.
Moving Average
Amphastar Pharmaceuticals’s value is way above its 50-day moving average of $49.66 and way higher than its 200-day moving average of $47.60.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 24.7% and 9.7%, respectively.
3. Dycom Industries (DY)
16% sales growth and 23.04% return on equity
Dycom Industries, Inc. provides specialty contracting services in the United States. The company offers various specialty contracting services, including program management, engineering, construction, maintenance, and installation services, such as placement and splicing of fiber, copper, and coaxial cables to telecommunications providers. It also provides tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; and installs and maintains customer premise equipment, such as digital video recorders, set top boxes, and modems for cable system operators. In addition, the company offers construction and maintenance services for electric and gas utilities, and other customers; and underground facility locating services, such as locating telephone, cable television, power, water, sewer, and gas lines for various utility companies, including telecommunication providers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.
Earnings Per Share
As for profitability, Dycom Industries has a trailing twelve months EPS of $7.41.
PE Ratio
Dycom Industries has a trailing twelve months price to earnings ratio of 14.32. Meaning, the purchaser of the share is investing $14.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.04%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9%, now sitting on 4.14B for the twelve trailing months.
Sales Growth
Dycom Industries’s sales growth is 5.4% for the present quarter and 16% for the next.
4. Copa Holdings, S.A. Copa Holdings, S.A. (CPA)
7.2% sales growth and 24.37% return on equity
Copa Holdings, S.A., through its subsidiaries, provides airline passenger and cargo services. The company offers approximately 104 daily scheduled flights to 54 destinations in 25 countries in North, Central, and South America, as well as the Caribbean from its Panama City hub. As of December 31, 2020, it operated a fleet of 77 aircraft comprising 70 Boeing 737-Next Generation aircraft and 7 Boeing 737 MAX 9 aircraft. Copa Holdings, S.A. was founded in 1947 and is based in Panama City, Panama.
Earnings Per Share
As for profitability, Copa Holdings, S.A. Copa Holdings, S.A. has a trailing twelve months EPS of $9.7.
PE Ratio
Copa Holdings, S.A. Copa Holdings, S.A. has a trailing twelve months price to earnings ratio of 10.87. Meaning, the purchaser of the share is investing $10.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.37%.
